Drug profile

The FDA adverse-event record for Milbemycin Oxime Praziquantel

12 FDA reports name Milbemycin Oxime Praziquantel, a lower-volume drug in the CVM extract. Species, reactions, and outcomes follow.

#2374 of 2,679
by report volume (all drugs)
12
adverse-event reports
8.3%
death-coded share
Dog
most-reported species
Verify with FDA CVM →

Corpus placement

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Milbemycin Oxime Praziquantel ranks #2299 of 2679 by total reports (12). Death-coded-share rank requires at least 50 reports. National dual: Milbemycin Oxime + Spinosad is #1 of 2679 drugs by total adverse-event reports (149,624) at death-coded-share rank 965 of 1130 drugs with at least 50 reports (2.3%); separately, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is #1 highest death-coded share at 97.8% (report rank #821).

149,624
Milbemycin Oxime + Spinosad reports (#1)
97.8%
Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) death share (#1)
#2299
This drug, reports of 2679

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Milbemycin Oxime Praziquantel has 12 reports now versus 10 in that prior snapshot: 2 more (20.0%).

Report change
+2
Death-coded reports
+0
Death-coded share
−1.7 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Milbemycin Oxime Praziquantel changes

Signature read: 12 reports place Milbemycin Oxime Praziquantel in the lower third of FDA AER volume (#2374 of 2,679).

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
1
Deaths Reported
8.3%
Death-coded share of reports

Active Ingredients

Milbemycin Oxime Praziquantel

Administration Routes

OralUnknown

Species Affected

Dog 12

Most Affected Breeds

Shepherd Dog - German 4
Crossbred Canine/dog 3
Retriever - Labrador 2
Pug 1
Dog (unknown) 1
Retriever (unspecified) 1

Most Reported Reactions

Neutrophilia 4
Sneezing 3
Listless 3
Not eating 3
Reduced responses 3
Difficulty standing 3
Falling 3
Polyuria 3
Decreased drinking 3
Fever 3
Tachycardia 3
Tachypnoea 3

Outcome Breakdown

Ongoing
6 (50.0%)
Outcome Unknown
5 (41.7%)
Euthanized
1 (8.3%)

Milbemycin Oxime Praziquantel: lower report volume in the FDA AER row

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

What to do with this drug

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Milbemycin Oxime Praziquantel (#2374 of 2,679 by report volume); death-coded 8.3%. PlainBreed drug row · report volume stamp 12 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →